Wide Ranks

IMCR

Immunocore Holdings plc

32.83

Top Statistics
Market Cap 1 B Forward PE -27.57 Revenue Growth 23.70 %
Current Ratio 3.78 Trailing PE 0.0000 Earnings Growth 822.00 %
Profit Margins -15.88 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -18.84 Enterprise / Revenue 4.12 Price To Sales Trailing12 Months 5.54
Profitability
Profit Margins -15.88 % Operating Margins -10.60 %
Balance Sheet
Total Cash 901 M Total Cash Per Share 18.01 Total Debt 481 M
Total Debt To Equity 127.32 Current Ratio 3.78 Book Value Per Share 7.55
All Measures
Short Ratio 3092.00 % Message Board Id finmb_133103539 Shares Short Prior Month 8 M
Return On Equity -0.1283 City Abingdon Uuid b7b7552a-a3f9-3661-bcfc-03291a3fce2e
Previous Close 32.45 First Trade Date Epoch Utc 1 B Book Value 7.55
Beta 0.7190 Total Debt 481 M Volume 196704
Price To Book 4.35 Fifty Two Week Low 29.72 Total Cash Per Share 18.01
Total Revenue 296 M Shares Short Previous Month Date 1 B Target Median Price 53.57
Max Age 86400 Recommendation Mean 1.80 Sand P52 Week Change 0.3133
Operating Margins -10.60 % Target Mean Price 52.51 Net Income To Common -47046000
Short Percent Of Float 0.1732 Implied Shares Outstanding 50 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 262350 Average Volume10days 262350
Total Cash 901 M Next Fiscal Year End 1 B Revenue Per Share 5.94
Held Percent Insiders 0.0524 Ebitda Margins -21.90 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 32.45
Target Low Price 18.58 Gmt Off Set Milliseconds -18000000 Fifty Day Average 32.23
Open 32.77 Free Cashflow 42 M Dividend Yield 0.00 %
Return On Assets -0.0522 Time Zone Short Name EST Trailing Eps -0.9500
Day Low 32.28 Address1 92 Park Drive Shares Outstanding 50 M
Price Hint 2 Target High Price 77.63 Website https://www.immunocore.com
52 Week Change -0.3774 Average Volume 358996 Earnings Quarterly Growth 864.20 %
Forward Eps -1.71 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 362.40 % Is_sp_500 False Regular Market Day High 33.32
Profit Margins -15.88 % Debt To Equity 127.32 Fifty Two Week High 76.98
Day High 33.32 Shares Short 7 M Regular Market Open 32.77
Industry Key biotechnology Earnings Growth 822.00 % Enterprise To Revenue 4.12
Revenue Growth 23.70 % Shares Percent Shares Out 0.1520 Operating Cashflow 22 M
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip OX14 4RY Quote Type EQUITY
Industry Biotechnology Long Name Immunocore Holdings plc Regular Market Day Low 32.28
Held Percent Institutions 0.9460 Current Price 32.83 Address2 Milton Park
Enterprise To Ebitda -18.84 Financial Currency USD Current Ratio 3.78
Gross Margins 29.55 % Industry Disp Biotechnology Number Of Analyst Opinions 14
Country United Kingdom Float Shares 41 M Two Hundred Day Average 44.62
Enterprise Value 1 B Price To Sales Trailing12 Months 5.54 Forward PE -27.57
Regular Market Volume 196704 Ebitda -64888000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.

It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma.

Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial.

Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.